AI-generated analysis. Always verify with the original filing.
Agenus Inc. reported financial results for the fourth quarter and full year ended December 31, 2025, including $4.2 million in pre-commercial product revenue from BOT+BAL early access programs and a full-year net loss of $3.1 million. Highlights include global expansion of early access programs with over 200 physician inquiries, 42% two-year overall survival in MSS mCRC, initiation of Phase 3 BATTMAN trial, and $91 million upfront from Zydus collaboration.
Event Type
Disclosure
Mandatory
Variant
8-K
and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193
Financial Statements and Exhibits. (d) Exhibit The following exhibit is furnished herewith: 99.1 Press Release dated March 16, 2026 SIGNATURES Pursuant to the r
| Metric | Value | Basis |
|---|---|---|
| Pre-commercial product revenue | $3.20 | |
| Other revenue, including non-cash royalty revenue | $31.10 | |
| Operating income | $14.40 | |
| Net loss | $-10.60 | |
| Pre-commercial product revenue | $4.20 | |
| Other revenue, including non-cash royalty revenue | $110.00 | |
| Operating income (loss) | $-20.20 | |
| Net loss | $-3.10 |